Travere Therapeutics, Inc. TVTX
Travere Therapeutics, Inc. (Nasdaq: TVTX) is a cardio-renal-metabolic drug developer. Its lead program, FILSPARI (sparsentan), is in Phase 3 for Primary IgA nephropathy (IgAN); also FSGS. Its next catalyst on record is sparsentan (Japan): Chugai regulatory filing in Japan (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: sparsentan (Japan) — Chugai regulatory filing in Japan (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| FILSPARI (sparsentan) | IgAN (full approval Sept 2024) and FSGS without nephrotic syndrome (full approval 2026-04-13) | small molecule | Approved |
| Thiola / Thiola EC (tiopronin) | Cystinuria | small molecule | Approved |
| pegtibatinase | Classical homocystinuria (Phase 3 HARMONY, enrollment restarted) | enzyme_replacement | Phase 3 |
| civorebrutinib | Primary membranous nephropathy (Phase 1/2 proof of concept); FSGS, MCD planned | small molecule | Phase 2 |
Recent results and decisions
- May 4, 2026started First new patient dosed in April 2026 in the restarted pivotal Phase 3 HARMONY study (about 70 patients, primary endpoint change in plasma tHcy weeks 6-12).
In April 2026, the Company dosed the first new patient following the study restart, with topline data anticipated in 2H 2027.
Filing - Apr 13, 2026approval FDA approved FILSPARI to reduce proteinuria in patients aged 8+ with FSGS without nephrotic syndrome, the first approved FSGS medicine; DUPLEX showed 48% vs 27% proteinuria reduction at Week 108 vs irbesartan in this subgroup (nominal p=0.0075).
FILSPARI is the first and only medicine approved by the FDA for the treatment of FSGS, marking its expansion beyond IgA nephropathy (“IgAN”) into a second rare kidney disease.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.